about
Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancerMolecular and functional analyses of the human and mouse genes encoding AFG3L1, a mitochondrial metalloprotease homologous to the human spastic paraplegia proteinHuman TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance.ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcriptionLocalization of the human NMDAR2D receptor subunit gene (GRIN2D) to 19q13.1-qter, the NMDAR2A subunit gene to 16p13.2 (GRIN2A), and the NMDAR2C subunit gene (GRIN2C) to 17q24-q25 using somatic cell hybrid and radiation hybrid mapping panelsMolecular cloning, expression and chromosomal localization of a human gene encoding a 33 kDa putative metallopeptidase (PRSM1)The sequence and analysis of duplication-rich human chromosome 16Aberrant CBFA2T3B gene promoter methylation in breast tumorsIsolation and characterization of transcribed sequences from a chromosome 16 hn-cDNA library and the physical mapping of genes and transcribed sequences using a high-resolution somatic cell panel of human chromosome 16Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3The gene for the human IgA Fc receptor maps to 19q13.4Smooth muscle myosin heavy chain locus (MYH11) maps to 16p13.13-p13.12 and establishes a new region of conserved synteny between human 16p and mouse 16Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosityThe gene for human interleukin 7 (IL7) is at 8q12-13ARA, a novel ABC transporter, is located at 16p13.1, is deleted in inv(16) leukemias, and is shown to be expressed in primitive hematopoietic precursorsNew regional localisations for HAGH and PGP on human chromosome 16Molecular cloning and physical and genetic mapping of a novel human Na+/H+ exchanger (NHE5/SLC9A5) to chromosome 16q22.1Assignment of the human CC chemokine gene TARC (SCYA17) to chromosome 16q13Molecular analysis of human chromosome 16 cosmid clones containing NotI sites.SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication.Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes.The oncogenic role of miR-155 in breast cancer.Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.Physical and genetic mapping of the dipeptidase gene DPEP1 to 16q24.3.Chromosomal assignment of the human SA gene to 16p13.11 and demonstration of its expression in the kidney.FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex.Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.Localization of the human GM-CSF receptor gene to the X-Y pseudoautosomal region.p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNAXI-006 induces potent p53-independent apoptosis in Ewing sarcoma.ACHF249 [D22S14] detects a common PstI RFLP and maps at 22cen----22q13.1.Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3.The application of delivery systems for DNA methyltransferase inhibitors.Ankrd11 is a chromatin regulator involved in autism that is essential for neural development.Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome.Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.A template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease.Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.Specific-site methylation of tumour suppressor ANKRD11 in breast cancer.Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.
P50
Q22004026-C33F3A71-FF78-4459-8C30-2DA27D6D1F40Q24291666-C17C0183-B8B6-46CD-BC32-2076C1A1AE78Q24294967-C8CA7DB3-5E82-41D4-9D43-1515815DD274Q24302477-B3DEB8BD-012E-4A18-9D66-A8483B0BC442Q24313117-49508927-6115-4B89-89D1-D7C498944362Q24314208-37305C25-BF7C-4047-BE84-42180E33E6CBQ24329232-5D4CD023-A536-47BA-A83D-92B4F7651602Q24804804-ED0DBF28-759D-4777-BCC5-D6729A43BA45Q28115090-074C40C3-F90D-425F-80A2-7CEC5BBA722BQ28236197-0930B0FD-B43C-4D28-BDC7-0DB8D138F1C1Q28240305-75DEE68A-D9BD-4F4B-9C50-EB1E0307CD76Q28258053-B777668F-0DCE-4A19-85FB-4416239FB7B6Q28272869-28C32AF2-B925-4AB4-BACF-95CB0A8A2B6BQ28279606-E6C53D99-0376-4AAA-AAE1-6FD56D182D05Q28280963-D225EB3F-645C-4765-972C-8B79CB373A11Q28287885-6AA350DE-CF48-4613-9058-C7AEE46E2528Q28301884-F5921839-FF32-40DF-A80D-1E9D84007C9AQ28306106-555CBAB6-5F0A-477B-A041-6BC31DC91602Q33223603-D5282510-238A-46CF-8061-B7DD58719AF8Q34073816-DA143F1C-543A-4EFB-A80E-CCF86FC625CEQ34147823-C01DFF62-010D-4EE6-94C5-86EA19991638Q34284424-F99CC676-27D8-49A4-A484-00AB379A2E06Q34288205-C83313A0-FEFB-4D0C-A133-06B0A8FE95BCQ34305972-7722BC26-E2B2-495F-A316-49248AC29C90Q34337778-DE185DED-1D4F-46B1-9F45-93D6BA234E74Q34476919-43105F6F-95FE-4809-BD91-6EC51986D627Q34622598-EDEDA9FC-A009-4450-ABC3-09626F30783DQ35001025-8FDDB460-3EDA-4507-AE01-193DE7EAC55DQ35659515-85D4194C-92BE-4438-B4CF-12ACCD7AD5F1Q35764901-51C3C1B5-DC5E-4517-95BD-8D84D6EE9B1EQ36068020-F1EAA151-AEAA-42A0-91DE-76A894716990Q36617573-E06E0C4B-08F1-428A-AD22-FFFEBF7060DFQ37911496-211D0F52-144D-42C9-9058-78496670DFB6Q38301892-1CB7581E-5D2D-4E35-9181-DBA0439C19E9Q38938740-53C63D35-84FB-436E-BFC5-0AA731167A09Q39043653-1CE32DFD-3658-43A2-B626-007ED19591AFQ39077961-530848AE-988E-4718-8687-37B15E1FAA49Q39152554-0BF73A2A-BFC2-4EBC-8FC7-3EF665B48DECQ39357893-79561090-65BC-499F-8F54-8CD2B44A3D9CQ39456285-E28C0AE2-6004-4D98-820F-35A2292B1668
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David F Callen
@nl
David F Callen
@sl
David F. Callen
@en
David F. Callen
@es
type
label
David F Callen
@nl
David F Callen
@sl
David F. Callen
@en
David F. Callen
@es
prefLabel
David F Callen
@nl
David F Callen
@sl
David F. Callen
@en
David F. Callen
@es
P106
P1153
7101835279
P21
P31
P496
0000-0002-6189-9991